Date Filed | Type | Description |
05/13/2013 |
SC 13D/A
| GAMCO INVESTORS, INC. ET AL reports a 0% stake in Obagi Medical Products, Inc. |
05/10/2013 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
05/06/2013 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)] |
04/29/2013 |
4
| Leslie Kristina M (Director) has filed a Form 4 on Obagi Medical Products, Inc.
Txns:
| Disposed/sold 4,890 shares
@ $24, valued at
$117.4k
|
|
04/29/2013 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
04/29/2013 |
4
| FITZGIBBONS ALBERT J III (Director) has filed a Form 4 on Obagi Medical Products, Inc. |
04/29/2013 |
4
| DUERDEN JOHN H (Director) has filed a Form 4 on Obagi Medical Products, Inc. |
04/29/2013 |
4
| Bartholdson John A. (Director) has filed a Form 4 on Obagi Medical Products, Inc. |
04/29/2013 |
4
| BADIE RONALD P (Director) has filed a Form 4 on Obagi Medical Products, Inc.
Txns:
| Disposed/sold 16,746 shares
@ $24, valued at
$401.9k
Disposed/sold 2,206 shares
@ $24, valued at
$52.9k
|
|
04/29/2013 |
4
| Taylor Mark Thomas (Senior Vice President) has filed a Form 4 on Obagi Medical Products, Inc. |
04/29/2013 |
4
| Goldstein David S. (Executive Vice President) has filed a Form 4 on Obagi Medical Products, Inc. |
04/29/2013 |
4
| Hunter Laura B. (VP and General Counsel) has filed a Form 4 on Obagi Medical Products, Inc. |
04/29/2013 |
4
| Romm Preston S (CFO and Exec. VP) has filed a Form 4 on Obagi Medical Products, Inc.
Txns:
| Disposed/sold 71,195 options to buy
@ $10, valued at
$712k
Disposed/sold 50,000 options to buy
@ $11.49, valued at
$574.5k
Disposed/sold 50,000 options to buy
@ $9.71, valued at
$485.5k
Disposed/sold 50,000 options to buy
@ $12.7, valued at
$635k
|
|
04/29/2013 |
4
| HUMMEL ALBERT F (President & CEO) has filed a Form 4 on Obagi Medical Products, Inc.
Txns:
| Disposed/sold 65,787 shares
@ $24, valued at
$1.6M
Disposed/sold 100,000 options to buy
@ $12.55, valued at
$1.3M
Disposed/sold 165,000 options to buy
@ $12.7, valued at
$2.1M
|
|
04/26/2013 |
8-K
| Quarterly results |
04/26/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
04/26/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
04/25/2013 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities |
04/25/2013 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
04/24/2013 |
10-K/A
| Annual Report for the period ended April 23, 2013 [amend] |
04/23/2013 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
04/22/2013 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
04/17/2013 |
SC 13D/A
| Form SC 13D - General statement of acquisition of beneficial ownership [amend] |
03/28/2013 |
SC 13D
| Obagi Medical Products, Inc. reports a 6.3% stake in Obagi Medical Products, Inc. |
03/25/2013 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
03/20/2013 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party |
03/20/2013 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer |
03/20/2013 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
03/14/2013 |
10-K
| Annual Report for the period ended March 14, 2013 |
03/14/2013 |
8-K
| Quarterly results |
03/08/2013 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
02/12/2013 |
SC 13G/A
| Obagi Medical Products, Inc. reports a 5.9% stake in Obagi Medical Products, Inc. |
12/10/2012 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
12/03/2012 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
|